AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip� microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries. Peter Mac researchers will use Affymetrix GeneChip technology to perform large-scale clinical studies. The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage and treat complex diseases. �We are excited about the opportunities created by the Translational Medicine Program, particularly the chance to apply new technologies to help us answer important clinical questions,� said Professor David Bowtell, Ph.D., director of research at the Peter MacCallum Cancer Centre. �We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genomics and genetics. We also see the program providing opportunities to interact with other centers worldwide that are involved in translational research.� To watch the full Affymetrix UserForum interview with Professor Bowtell, please visit: http://www.affymetrix.com/userForum/news/collaborations/bowtell.uf �Affymetrix is excited to be working with a leading research organization such as the Peter MacCallum Cancer Centre to help bring more effective personalized tests and therapies to market faster,� said Robert Wells, vice president, International Markets Group and Corporate Affairs at Affymetrix. �Together, we hope to accelerate clinical research, improve patient care, and open the door to new genomic applications.� Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and�diagnostics�community through its Translational�Medicine�Program to develop�molecular signatures for improving patient care. Affymetrix GeneChip microarray technology helps researchers to diagnose and�tailor treatments for individual patients�by identifying and measuring the genetic information associated with complex diseases. The�Translational�Medicine�Program complements the Powered by Affymetrix� program, which enables companies to license GeneChip technology to create innovative, custom-designed microarray products based on signatures such as those of our translational medicine partners. This technology is already being used in many applications, including diagnostics, forensics, animal, industrial and food testing. Millennium Science Pty. Ltd. will supply the Affymetrix microarray technology and provide technical support to the Peter Mac Cancer Centre. Since being founded in 1999, Millennium Science has grown into a leading distributor of instrumentation and reagents for the biotechnology research and industrial markets across Australia and New Zealand. About Peter MacCallum Cancer Centre As Australia�s foremost cancer centre, Peter Mac provides quality treatment and support to patients and their families. Underpinned by research and the best evidence available, Peter Mac broadly influences cancer care in the community through multi-disciplinary partnerships, research and education. The Research Division is located at Peter Mac, East Melbourne. Peter Mac Research employs nearly 300 staff, making it not only Australia's largest, but also one of the world's largest groups dedicated to cancer research. Research in the Division is undertaken within the broad framework of research programs in Cellular & Molecular Biology, Cancer Immunology and Cancer Genomics & Genetics. The latter program is home to several large collaborative cancer studies, including kConFab, which focuses on familial breast cancer, and the Australian Ovarian Cancer Study. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip� technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the outcome of the collaboration with the Peter MacCallum Cancer Centre discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip(R) microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries. Peter Mac researchers will use Affymetrix GeneChip technology to perform large-scale clinical studies. The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage and treat complex diseases. "We are excited about the opportunities created by the Translational Medicine Program, particularly the chance to apply new technologies to help us answer important clinical questions," said Professor David Bowtell, Ph.D., director of research at the Peter MacCallum Cancer Centre. "We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genomics and genetics. We also see the program providing opportunities to interact with other centers worldwide that are involved in translational research." To watch the full Affymetrix UserForum interview with Professor Bowtell, please visit: http://www.affymetrix.com/userForum/news/collaborations/bowtell.uf "Affymetrix is excited to be working with a leading research organization such as the Peter MacCallum Cancer Centre to help bring more effective personalized tests and therapies to market faster," said Robert Wells, vice president, International Markets Group and Corporate Affairs at Affymetrix. "Together, we hope to accelerate clinical research, improve patient care, and open the door to new genomic applications." Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and diagnostics community through its Translational Medicine Program to develop molecular signatures for improving patient care. Affymetrix GeneChip microarray technology helps researchers to diagnose and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. The Translational Medicine Program complements the Powered by Affymetrix(TM) program, which enables companies to license GeneChip technology to create innovative, custom-designed microarray products based on signatures such as those of our translational medicine partners. This technology is already being used in many applications, including diagnostics, forensics, animal, industrial and food testing. Millennium Science Pty. Ltd. will supply the Affymetrix microarray technology and provide technical support to the Peter Mac Cancer Centre. Since being founded in 1999, Millennium Science has grown into a leading distributor of instrumentation and reagents for the biotechnology research and industrial markets across Australia and New Zealand. About Peter MacCallum Cancer Centre As Australia's foremost cancer centre, Peter Mac provides quality treatment and support to patients and their families. Underpinned by research and the best evidence available, Peter Mac broadly influences cancer care in the community through multi-disciplinary partnerships, research and education. The Research Division is located at Peter Mac, East Melbourne. Peter Mac Research employs nearly 300 staff, making it not only Australia's largest, but also one of the world's largest groups dedicated to cancer research. Research in the Division is undertaken within the broad framework of research programs in Cellular & Molecular Biology, Cancer Immunology and Cancer Genomics & Genetics. The latter program is home to several large collaborative cancer studies, including kConFab, which focuses on familial breast cancer, and the Australian Ovarian Cancer Study. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the outcome of the collaboration with the Peter MacCallum Cancer Centre discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.